Anirvan Ghosh

Anirvan Ghosh

Company: UNITY Biotechnology

Job title: Chief Executive Officer


Anirvan is the CEO of UNITY Biotechnology, a company dedicated to developing therapeutics to slow, halt, or reverse diseases of aging. Prior to joining UNITY in March 2020, Anirvan served as Senior Vice President and Head of Research and Early Development at Biogen. During his tenure at Biogen, Anirvan led a team of 350 scientists and clinicians responsible for preclinical, and clinical Phase 1 and Phase 2 studies in all of Biogen’s disease areas and led a marked expansion of its early clinical portfolio. Anirvan was also involved in expanding the portfolio through key partnerships, including acquisition of early stage assets in Alzheimer’s Disease, Schizophrenia, and Ophthalmology, and several multi-asset platform collaborations.


Prior to joining Biogen, Anirvan served as Vice President and global head of neuroscience discovery and biomarkers at Roche. Previously he was on the faculty at The Johns Hopkins School of Medicine and Chair of Neurobiology at University of California, San Diego. Anirvan received his BS in physics from California Institute of Technology and his Ph.D. in neuroscience from Stanford University. He completed his postdoctoral work at Harvard Medical School. The impact of his scientific contributions is reflected in over 100 scientific publications in top-tier journals, including Science and Nature. He has been a recipient of numerous awards, and as a recognized scientific leader he has organized and chaired leading scientific meetings including Gordon Research Conferences and Cold Spring Harbor Meetings.


Opening Keynote: Unity Biotechnologies’ Pipeline Progression: From Mouse Models to First-in-Human Trials 9:00 am

Examine the role of senescent cells in diseases of aging and the promise of transformative medicines Explore discovery and development of senolytic agents, a new class of therapeutics Targeting senescence biology in first-in-human trials in diabetic retinopathies Understand the potential impact of targeting senescence and related biologies of aging in diseases of the eye, brain…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.